Hyperpolarized MR Imaging With Carbon-13 Pyruvate in the Human Body

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT06645691

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06645691
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Singapore (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06645691. Allocation not applicable; no masking; primary purpose diagnostic. Start 2024-10-17 (actual); primary completion 2028-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Hyperpolarized MR Imaging With Carbon-13 Pyruvate in the Human Body
Acronym
POLARIC-13
Condition
Heart Failure
Condition
Cardiometabolic Syndrome
Condition
Cancer Diagnosis
Condition
Cardiovascular Diseases
Condition
Healthy Volunteers
Intervention (Drug)
Hyperpolarized 13C-pyruvate
Lead sponsor
National Heart Centre Singapore (class: other)
Collaborator
National Medical Research Council (NMRC), Singapore (class: other government)

Record details

Record id
cardio:ct-nct06645691
Content hash
4179fe9b1ab46cdfe6deee90bbf0f902ed38645b0f89bdc65d6a14bc8441c48f